---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-027034"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2023-09-28T23:59:59+00:00"
generated_at: "2026-06-10T08:02:14.737226+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OPKO subsidiary ModeX awarded $59M BARDA contract for multispecific antibody against SARS-CoV-2, up to $168M total

## Summary
- ModeX (OPKO subsidiary) received initial $59M from BARDA for MSTAR multispecific antibody Phase 1 trial against SARS-CoV-2.
- Up to $109M additional contingent on milestones for developing antibodies against influenza and other viral pathogens.
- Total potential contract value $168M; part of HHS' Project NextGen for innovative COVID-19 vaccines and therapeutics.
- Gene-based delivery methods (mRNA/DNA vectors) will be developed to leverage body's natural protein production.
- In March 2023, ModeX entered exclusive worldwide license with Merck for Epstein-Barr virus vaccine candidate MDX2201.

## SEC filing metadata
- accession: 0001437749-23-027034
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2023-09-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774923027034/0001437749-23-027034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774923027034/opk20230928c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-027034
- JSON: https://secwatch.observer/filing/0001437749-23-027034.json
- Plain text: https://secwatch.observer/filing/0001437749-23-027034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.